5934
K. Bujnowski et al. / Tetrahedron 68 (2012) 5925e5934
871.4351; found 871.4376 (error: 2.7 ppm). IR: 3400, 3240, 2960,
1700, 1600, 1535, 1470 cmꢁ1
(error: 2.6935 ppm). IR: 3408 (br.), 2968, 1723, 1594, 1372,
1240 cmꢁ1
.
.
Synthesis of 3-(50-Methyl-30-propylimino) hexenylrifamycin SV
(3) (of type E1): 1.6 g of 3-formylrifamycin SV (2 mmol) was added to
a solution containing: 15.0 ml of methanol, 0.6 g of acetic acid, 0.6 g
(w10 mmol) of propylamine and 2.0 g (w20 mmol) of 4-methyl-2-
pentanone. The system was stirred at 40e45 ꢀC for 4 h, The crystal-
line blue product was separated according to 5.2-B. 1,05 g of 3 was
obtained. Yield 61.8%. See Supplementary data for 13C and 1H NMR
spectroscopic data. MS (ESI): m/z (%): 871.5 (100.0) [MþNa]þ, 812.4
(71.5) [MþNaꢁC3H7NH2]þ, 849.5 (45.5) [MþH]þ, 790.4 (15.2)
[MþHꢁC3H7NH2]þ. HRMS calcd for [MþNa]þ C47H64N2O12Na
871.4351;found871.4362(error:1.2ppm). IR:3409, 3246, 2968,1704,
Acknowledgements
The above research project was financially supported by War-
saw University of Technology. The authors kindly thank Mr. Norbert
Langwald and Ms. Renata Przedpe1ska for the editorial assistance,
and Mr. Gilbert Zwick for recording the MS-ESI spectra.
Supplementary data
Supplementary data associated with this article can be found in
clude MOL files and InChiKeys of the most important compounds
described in this article.
1596, 1472, 1247 cmꢁ1
.
Synthesis of 3-(30-Cyclohexylimino)octenylrifamycin SV (4) (of
type E2): 1.6 g of 3-formylrifamycin SV (2 mmol) was added to
a solution containing: 15.0 ml of methanol, 0.6 g of acetic acid,
1.0 g (w10 mmol) of cyclohexylamine and 2.3 g (w20 mmol) of 2-
heptanone. The system was stirred at w45 ꢀC for 2/3 h. The
crystalline dark blue product was separated according to 6.2-A.
0.92 g of 4 was obtained. Yield 51.0%. See Supplementary data for
13C and 1H NMR spectroscopic data. MS (ESI): m/z (%): 925.5
(100.0) [MþNa]þ, 908.5 (38.1) [MþH]þ, 826.4 (32.7) [MþNa-
C6H11NH2]þ. HRMS calcd for [MþNa]þ C51H70N2O12Na 925.4821;
found 925.4830 (error: 1.0 ppm). IR: 3458 (br), 2936, 2864, 1716,
References and notes
1. Wrona, I. E.; Agouridas, V.; Panek, J. S. C. R. Chim. 2008, 11, 1483.
2. Lal, R.; Lal, S. BioEssays 1994, 16, 211.
3. Floss, H. G.; Yu, T. W. Chem. Rev. 2005, 105, 621.
4. Aristoff, P. A.; Garcia, G. A.; Kirchhoff, P. D.; Hollis Showalte, H. D. Tuberculosis
2010, 90, 94.
5. Mitchison, D. A.; Fourie, P. B. Tuberculosis 2010, 90, 177.
6. Cole, S. T. Res. Microbiol. 1996, 147, 48.
7. Bujnowski, K.; Synoradzki, L.; Dinjus, E.; Zevaco, T.; Augustynowicz-Kopec, E.;
ꢀ
1599, 1473, 1237 cmꢁ1
.
Zwolska, Z. Tetrahedron 2003, 59, 1885.
Synthesis of 3-(30-Isopropylimino)nonenylrifamycin SV (5) (of
type E2): 1.6 g of 3-formylrifamycin SV (2 mmol) was added to a so-
lution containing: 15.0 ml of methanol, 0.6 g of acetic acid, 0.6 g
(w10 mmol) of isopropylamine and 2.5 g (w20 mmol) of 2-octanone.
The system was stirred at w40 ꢀC for 3.0 h. The crystalline dark blue
product was separated according to 5.2-A. 1.16 g of 5 was obtained.
Yield 66.3%. See Supplementary data for 13C and 1H NMR spectro-
scopic data. MS (ESI): m/z (%): 899.5 (100.0) [MþNa]þ, 840.4 (64.8)
[MþNaꢁC3H7NH2]þ, 877.5 (37.0) [MþH]þ HRMS calcd for [MþNa]þ
C49H68N2O12Na 899.4664; found 899.4638 (error: 2.95 ppm). IR:
8. Bujnowski K.; Synoradzki L.; Bojarska-Dahlig H.; Dinjus E.; Leitner W.; Gassner
F., to Warsaw University of Technology, PL Pat. 2003, 184, 862.
9. Bujnowski, K.; Synoradzki, L.; Zevaco, T.; Dinjus, E.; Augustynowicz-Kopec, E.;
ꢀ
Zwolska, Z. Eur. J. Org. Chem. 2006, 4155.
10. Bujnowski K.; Synoradzki L.; Bojarska-Dahling H.; Dinjus E.; Gassner F., to
Warsaw University of Technology, PL Pat. 2003, 185, 662.
11. Carey, F. A.; Sundberg, R. J. Advanced Organic Chemistry Part B: Reactions and
Synthesis; Plenum: New York, NY and London, 1990, pp 58e60.
12. Cricchio, R.; Tamborini, G.; Bravo, P.; Gaudiano, G. IlFarmacodEd. Sc.1974, 29, 358.
13. Cricchio R., to Gruppo Lepetit S.p.A., U.S. Patent 1,389,100, 1972.
14. Carey, F. A. Organic Chemistry; The McGraw-Hill Companies: 1996, pp 741e747.
15. March, J. Advanced Organic Chemistry; John Wiley: 1992, pp 937e945.
16. Hammet, L. P. Physical Organic Chemistry; McGraw-Hill Book: New York, NY,
1940; p 333.
3412, 3265, 2972, 2935, 1720, 1728, 1599, 1472, 1241 cmꢁ1
Synthesis of 3-(50-Methyl-30-oxo)hexenylrifamycin SV (6) (of
type F):
.
17. I.Choma, Antibiotics: TLC Analytics in Encyclopedia of Chromatography, 3rd ed.,
Ed. J.Cazes, vol. 1; pp 89e95.
18. Kanfer, I.; Skinner, M. F.; Walker, R. B. J. Chromatogr., A 1998, 812, 255.
19. Henwood, S. Q.; Liebenberg, W.; Tiedt, L. R.; Lotter, A. P.; De Villiers, M. M. Drug
Dev. Ind. Pharm. 2001, 27, 1017.
To 0.85 g (1 mmol) of 2 in 80 ml of methanol, 100 ml of an
aqueous solution containing 5.0 g of Na2HPO4ꢂ12H2O was slowly
added (attention: a too rapid mixing of the solutions leads to
a substantial foaming) and the homogeneous system obtained was
stirred at 40e45 ꢀC. The reaction progress was monitored chro-
matographically (TLC), observing the gradual disappearance of the
initial imine (2) blue spot, and the increase of the product red spot
Rf6<Rf2. After 4 h methanol was distilled off under vacuum
(p¼200 mmHg, temp¼60 ꢀC), and the remaining aqueous sus-
pension was extracted twice with chloroform (50 mlþ30 ml). The
chloroform extract was washed twice with 200 ml of water, while
adjusting pH of the aqueous phase during first washing with di-
luted H2SO4 to reach pHw2.0. The organic phase was dried with
anhydrous sodium sulfate, and after filtering off the drying agent,
concentrated to a volume of w15 ml, and left for 16 h at w0 ꢀC. The
fine crystalline red product was filtered off, washed with cold
(w0 ꢀC) chloroform and hexane and dried under vacuum. Yield
0.28 g (34.7%). See Table 3 for 13C and 1H NMR spectroscopic data.
MS (ESI) (negative ionization): m/z (%): 806.4 (100.0) [MꢁH]ꢁ.
HRMS calcd for [MꢁH]ꢁ C44H56NO13 806.37462; found 806.37679
20. Bujnowski K.; Synoradzki L.; Bojarska-Dahlig H.; Dinjus E., to Warsaw Univer-
sity of Technology, PL Pat. 2005, 188, 889.
21. Taguchi, M.; Yamana, Y.; Aikawa, N.; Trukamoto, G. Chem. Pharm. Bull. 1988, 36,
4157.
22. Taguchi, M.; Aikawa, N.; Tsukamoto, G. Bull. Chem. Soc. Jpn. 1988, 61, 2431.
23. Santos, L.; Fant, F.; Madeiros, M. A.; Borremans, F. A. M.; Costa, M. C.; Curto, M.
J. M. Magn. Reson. Chem. 2000, 38, 937.
24. Santos, L.; Medeiros, M. A.; Santos, S.; Costa, M. C.; Tavares, R.; Curto, M. J. M. J.
Mol. Struct. 2001, 563e564, 61.
25. Rubio, E.; Merino, I.; Garcia, A. B.; Cabal, M. P.; Ribas, C.; Bayod-Jasanada, M. J.
Mol. Struct. 2005, 43, 269.
26. (a) Friebolin, H. In Basic One- and Two-Dimensional NMR Spectroscopy; VCH Ver-
lagsgesellschaft mbH:Weinheim,1993; pp88e91; (b) Kalinowski, H. O.; Berger, S.;
Braun, S. In 13C NMR Spektroskopie; Georg Thieme: Stuttgart, 1984; pp 220e227.
27. John McMurry in Organic Chemistry, 5th ed.; Brooks/Cole
A Division of
Thomson Learning: 2000, pp 770e774.
28. Carey, F. A.; Sundberg, R. J. In Advanced Organic Chemistry: Part A: Structure and
Reactivity Plenum: New York, NY and London, 1990; p 461.
29. Kharash, M. S.; Richlin, J.; Mayo, F. R. J. Am. Chem. Soc. 1940, 62, 494.
30. Emerson, W. S.; Hess, S. M.; Uhle, F. C. J. Am. Chem. Soc. 1941, 63, 872.
31. Crampton, M. R.; Lord, S. D.; Millar, R. J. Chem. Soc., Perkin Trans. 1 1997, 2, 909.
32. Bujnowski K.; Synoradzki L.; Dinjus E.; Zevaco T., to Warsaw University of
Technology, Process for the preparation of N-substituted 3-(30-imino) alkyli-
denylrifamycin SV Pat. Appl. PL391473 (A1), 2010.